Odysight.ai receives $3.3M purchase order from Fortune 500 medical partner for FY2024

Odysight.ai Inc.

Expanded PO from Fortune 500 orthopaedic company totals $3.3M for fiscal year 2024.
Visual technology integrated into partner's FDA-approved minimally invasive surgical device.
Builds on prior January 2023 announcement; company expects substantial future growth.
CEO Yehu Ofer: trusted by Fortune 500 in critical medical technology field.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.